Zheng Quan Shi Bao·2025-08-03 22:41Core Viewpoint - The stock of Angli Kang (002940) has experienced significant volatility, with a cumulative increase of over 20% in two consecutive trading days, prompting the company to issue a risk warning [1] Group 1: Stock Performance and Trading Activity - Angli Kang's stock price has shown a remarkable upward trend since June, achieving a maximum cumulative increase of 360% during this period [3] - The company has confirmed that there are no undisclosed significant matters affecting its stock price and that its operational status remains normal [1] - The first phase of the employee stock ownership plan holds 4.3311 million shares, accounting for 2.15% of the total share capital, with potential for stock sales before the plan's expiration on November 2, 2025 [5] Group 2: Innovation Drug Projects - The company is currently focused on its ALK-N001 project, which is in Phase I clinical trials as of the announcement date [1] - There is an ongoing interest in the ALK-N002 project, which is still in the candidate selection phase and has not yet finalized specific drug candidates [2] - The company emphasizes the long cycle, high investment, and uncertainty associated with innovative drug development [2] Group 3: Business Overview - Angli Kang's pharmaceutical business includes chemical raw materials, chemical preparations, and pharmaceutical excipients, with a focus on high-purity plant-derived cholesterol and its derivatives [2]